Código QR (código de barras bidimensional)

Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review

Atypical hemolytic uremic syndrome (aHUS) represents an uncommon, life-threatening complement-mediated thrombotic microangiopathy that is linked to both significant renal and extrarenal complications. Eculizumab, a monoclonal antibody targeting complement component C5, has dramatically improved pati...

ver descrição completa

Na minha lista:
Principais autores: Dandan Zhang, Yichen Xiao, Hualin Ma
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2026-05-01
coleção:Frontiers in Pharmacology
Assuntos:
atypical hemolytic uremic syndrome
complement inhibitor
dose individualization
eculizumab
thrombotic microangiopathy
treatment discontinuation
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fphar.2026.1834141/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados